Ability Biologics is a Montreal-based cell targeting company focused on developing antibody therapeutics. Its AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen–antibody interactions to generate fully human, IgG-based multi-specific antibodies of high selectivity and affinity. The company’s antibodies are designed to respond to environmental signals within the cellular microenvironment, enabling logic-gated therapeutics. Led by CEO Giles Day, Ability Biologics emphasizes tried-and-tested IgG formats to simplify manufacturing, storage and administration and to reduce risks tied to complex formats and immunogenicity. The company intends to use newly raised funds to expand operations and its R&D sector. Ability Biologics completed a Seed financing to support these development and scaling plans. Ability Biologics uses its AbiLeap™ discovery engine—an AI platform combined with a large antibody–antigen interaction database built from more than five years of discovery data and public and private sources—to systematically generate logic-enabled, fully human antibodies. The company aims to create antibodies that are logic-gated to target specific tissues and cells based on local microenvironment cues such as pH, temperature, or metabolites. Launched by Amplitude Ventures with co-founders Giles Day (CEO) and Jean-Philippe Bürckert (Vice President of Technology), Ability has established a partnership with Charles River Laboratories for drug discovery and non-clinical development collaboration. The company intends to use its new funding to continue developing its solutions and advance its discovery engine. Financially, Ability closed a $12M seed financing to support these development efforts.

Total raised

$30M

Funding rounds

2

Latest round

Seed

Latest activity

Jun 2024